LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—

Filed today

—

Companies tracked

NSE & BSE

Listed on

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.

Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split

Data sourced from BSE India corporate announcements. More categories will be added over time.

Sun Pharma Advanced Research Company Ltd

SPARC sells Priority Review Voucher for US $195 million

ORDERS ▲ Positive Development LOW RISK

📅 Filed on BSE: 30 Apr 2026, 09:06 AM IST · BSE ID: 2b1442d1-bc1e-4664-b83c-2301d6020180

View Original BSE Filing (PDF)

💡

In Simple Terms

SPARC sold a valuable US drug regulatory approval voucher to another company for US $195 million in cash.

🤖 AI Summary

SPARC sold Priority Review Voucher for US $195 million to unrelated entity
Transaction is not related-party deal; counterparty holds zero shareholding in SPARC
No special governance rights, director appointments, or share issuance terms attached
Material event disclosed under SEBI Regulation 30 on April 30, 2026

🔢 Key Numbers — exact figures from BSE filing, not rounded

Sale proceeds

US $195 million

🏢 How This Affects the Company

📈

Business Impact

PRV sale does not directly impact core pharmaceutical R&D operations but represents monetization of regulatory assets accumulated from prior drug development programs.

💰

Financial Impact

One-time inflow of US $195 million strengthens cash position and balance sheet. Impact on reported earnings depends on timing of revenue recognition under accounting standards.

👥 What This Means For Shareholders

✅

Action Required

No action required. Material event is completed and disclosed.

👤

Who Is Affected

All shareholders benefit equally from US $195 million cash inflow with no selective impact. No new debt, equity issuance, or control changes.

🔍

Management Signal

Management chose to monetize regulatory asset rather than retain for internal pipeline use, suggesting either capital redeployment or portfolio optimization strategy.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events

Q1 FY27 balance sheet filing — verify US $195 million cash receipt and timing of earnings recognition

Management commentary on use of proceeds — track capital allocation strategy and R&D investment plans

Next PRV-related transaction or regulatory asset monetization announcements

LOW RISK Clean, non-related-party transaction with transparent disclosure. No governance red flags, no counterparty concentration risk, no contingent liabilities disclosed.

💡 Investor Takeaway

SPARC received US $195 million in cash from Priority Review Voucher sale to unrelated entity. No related-party ties, equity dilution, or special governance rights granted. One-time transaction does not indicate operational business momentum.

⚖️ Strengths & Concerns

✅ Positives

US $195 million non-dilutive cash inflow with no equity issuance or control implications
Clean transaction structure — unrelated counterparty eliminates related-party risk and governance concerns

⚠️ Concerns

PRV sale is one-time non-recurring event; does not reflect sustainable operational or product pipeline strength
No disclosure of buyer identity or transaction execution timeline reduces transparency for shareholders

📑 More from Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research reports (Loss) of ₹2,458 lakhs in Q2 FY27

RESULTS · 02 Nov 2026

Sun Pharma Advanced Research Board Meeting on Nov 2, 2026 for Unaudited Results

BOARD · 22 Oct 2026

Sun Pharma Advanced Research Company Ltd.: Anil Raghavan Appointed MD & CEO

MANAGEMENT · 13 Jul 2026

Sun Pharma Advanced Research Co. Ltd. - Two Senior Managers Retire

MANAGEMENT · 26 Jun 2026

Sun Pharma Advanced Research Company Board to Consider Audited Financial Results

BOARD · 11 May 2026

SPARC: Operations Head Dr. Shravanti Bhowmik Resigns, Transitions Within Group

MANAGEMENT · 03 Apr 2026

All BSE filings we have analysed for Sun Pharma Advanced Research Company Ltd.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.